Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.

Aspenberg P, Malouf J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Caeiro JR, Marin F, Marin F

The Journal of bone and joint surgery. American volume1 Nov 2016Cited by 46 (Europe PMC)

PMID27852903PMCIDPMC5551693DOI10.2106/jbjs.15.01217PepBankPUB-27852903

Source link PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, teriparatide shortened TUG time versus risedronate at 6, 12, 18, and 26 weeks.
In plain wordsAfter hip fracture, patients completed the movement test faster with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTimed Up-and-Go test
Study
n = 171
Comparator
Risedronate
Analysis
Secondary
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Measurements
TUG difference
−5.7 seconds
6 weeks
TUG difference
−4.4 seconds
12 weeks
TUG difference
−3.1 seconds
18 weeks
TUG difference
−3.1 seconds
26 weeks
Source sentences
Summary
The teriparatide group completed the TUG test in a shorter time at 6, 12, 18, and 26 weeks (differences of -5.7, -4.4, -3.1, and -3.1 seconds, respectively; p = 0.021 for the overall difference).
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290301
02HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, teriparatide reduced post-TUG pain versus risedronate at 12 and 18 weeks.
In plain wordsAfter hip fracture, pain after the movement test was lower with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePost-TUG pain VAS
Study
n = 171
Comparator
Risedronate
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Measurements
Adjusted absolute difference in post-TUG pain VAS
10.6 mm
12 weeks, teriparatide versus risedronate
Adjusted absolute difference in post-TUG pain VAS
11.9 mm
18 weeks, teriparatide versus risedronate
Source sentences
Summary
They also reported less pain on a visual analog scale immediately after the TUG test at 12 and 18 weeks (adjusted absolute differences of 10.6 and 11.9 mm, respectively; p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290302
03HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, SF-36 scores did not differ significantly between teriparatide and risedronate.
In plain wordsAfter hip fracture, quality of life scores were similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSF-36 score
Study
n = 171
Comparator
Risedronate
Analysis
Secondary
Outcome group
Quality of life · Whole body
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant between-group differences in the SF-36 score, Charnley hip pain score, ability to walk, or use of walking aids during follow-up.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290303
04HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, Charnley hip pain scores did not differ significantly between teriparatide and risedronate.
In plain wordsAfter hip fracture, Charnley pain scores were similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCharnley hip pain score
Study
n = 171
Comparator
Risedronate
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant between-group differences in the SF-36 score, Charnley hip pain score, ability to walk, or use of walking aids during follow-up.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290304
05HumanRandomized controlled trialSafety outcome
After pertrochanteric hip fracture, mild hypercalcemia was more frequent with teriparatide than risedronate.
In plain wordsAfter hip fracture, mildly high calcium was more frequent with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMild hypercalcemia
Study
n = 171
Comparator
Risedronate
Analysis
Secondary
Outcome group
Adverse events · Endocrine and hormones
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Mild hypercalcemia and hyperuricemia were more frequent with teriparatide.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290311
06HumanRandomized controlled trialSafety outcome
After pertrochanteric hip fracture, hyperuricemia was more frequent with teriparatide than risedronate.
In plain wordsAfter hip fracture, high uric acid was more frequent with teriparatide than risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseHyperuricemia
Study
n = 171
Comparator
Risedronate
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Mild hypercalcemia and hyperuricemia were more frequent with teriparatide.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290312
07HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, walking ability did not differ significantly between teriparatide and risedronate.
In plain wordsAfter hip fracture, walking ability was similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAbility to walk
Study
n = 171
Comparator
Risedronate
Analysis
Exploratory
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant between-group differences in the SF-36 score, Charnley hip pain score, ability to walk, or use of walking aids during follow-up.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290305
08HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, radiographic healing at 6, 12, and 26 weeks did not differ significantly between teriparatide and risedronate.
In plain wordsAfter hip fracture, healing on imaging was similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadiographic healing
Study
n = 171
Comparator
Risedronate
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290307
09HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, implant failure did not differ significantly between teriparatide and risedronate, with 7 versus 8 cases.
In plain wordsAfter hip fracture, implant failure was similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMechanical implant failure
Study
n = 171
Comparator
Risedronate
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Measurements
Mechanical failure of the implant
7 cases
teriparatide
Mechanical failure of the implant
8 cases
risedronate
Source sentences
Summary
Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290308
10HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, loss of reduction did not differ significantly between teriparatide and risedronate, with 2 versus 4 cases.
In plain wordsAfter hip fracture, loss of fracture alignment was similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLoss of reduction
Study
n = 171
Comparator
Risedronate
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Measurements
Loss of reduction
2 cases
teriparatide
Loss of reduction
4 cases
risedronate
Source sentences
Summary
Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290309
11HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, nonunion did not differ significantly between teriparatide and risedronate, with no cases reported.
In plain wordsAfter hip fracture, nonunion was similar with teriparatide and risedronate, with no cases reported.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonunion
Study
n = 171
Comparator
Risedronate
Analysis
Exploratory
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Measurements
Nonunion
0 cases
both groups
Source sentences
Summary
Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290310
12HumanRandomized controlled trialEfficacy outcome
After pertrochanteric hip fracture, walking aid use did not differ significantly between teriparatide and risedronate.
In plain wordsAfter hip fracture, walking aid use was similar with teriparatide and risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUse of walking aids
Study
n = 171
Comparator
Risedronate
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
20 μg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant between-group differences in the SF-36 score, Charnley hip pain score, ability to walk, or use of walking aids during follow-up.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2).
Summary · context
Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported.
Summary · context
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis.
Report a problemFND-2785290306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.